Fort Myers-based NeoGenomics Inc. has revised its outlook for fourth-quarter earnings.
The company now expects revenues in the range of $12 million to $12.5 million for the quarter. That’s up from its original estimate of $11.4 million to $12 million, which it released on Oct. 19.
The company expects to be profitable in the fourth quarter, with earnings of up to 1 cent a share.
Doug VanOort, the company’s chairman and CEO, said, “We experienced strong year-over-year revenue growth in both October and November, and our rate of growth has continued to accelerate. This growth is broad-based, and is the result of a variety of growth initiatives we have made over the last eighteen months.”
The company offers genetic testing, focused on the diagnosis of cancer.
Marco Island Academy ribbon cutting
Scripps Interactive Newspapers Group
Comments » 0
Be the first to post a comment!
Share your thoughts
Comments are the sole responsibility of the person posting them. You agree not to post comments that are off topic, defamatory, obscene, abusive, threatening or an invasion of privacy. Violators may be banned. Click here for our full user agreement.